Zdrowie i gospodarka · 25/10/2017
FDA Clears Way for Norgestrel Tablet Approval
The FDA has determined that the 0.075mg OVRETTE (norgestrel) tablet was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of the generic version.